Novo Nordisk’s Dual Narrative: Promising Hemophilia Data and Steady Buybacks vs. a Glitch in the Obe
Novo Nordisk ended the week at €43.32, notching a 1.29% gain in Friday’s session. The move capped a…
Novo Nordisk’s Dual Narrative: Factory Start-Up and Pipeline Showdown at ADA
Novo Nordisk opens a Czech GLP-1 plant on June 12 and presents critical CagriSema data at ADA as…
Denmark’s Growth Upgrade and a DKK 11.2bn Buyback Propel Novo Nordisk’s Narrative
Copenhagen revises 2026 GDP forecast to 2.7% on booming pharma led by Novo Nordisk, despite US pricing headwinds…
Novo Nordisk’s Comeback Narrative Gains Steam from Analyst Upgrade, Clinical Data and Canadian Acc
Novo Nordisk shares surge 31% from March lows as Hedgeye forecasts 52-117% upside, fueled by oral obesity drug…